{
    "clinical_study": {
        "@rank": "41730", 
        "arm_group": [
            {
                "arm_group_label": "Tenofovir + Telbivudine", 
                "arm_group_type": "Experimental", 
                "description": "Tenofovir (300 mg/day) plus telbivudine (600 mg/day)."
            }, 
            {
                "arm_group_label": "Tenofovir", 
                "arm_group_type": "Active Comparator", 
                "description": "In tenofovir arm subjects will receive tenofovir (300 mg) once daily."
            }
        ], 
        "brief_summary": {
            "textblock": "The relevant data will be prospectively collected included patient demographics, clinical,\n      all laboratory variables including virological tests, genotyping by direct sequencing,\n      abdominal ultrasound, and upper gastrointestinal (GI) endoscopy. Trans jugular liver biopsy\n      (TJLB) and hepatic venous pressure gradient (HVPG) will be done in patients when it was not\n      evident whether the underlying liver disease was chronic based on clinical, biochemical,\n      radiological investigations, and upper GI endoscopy. Severity of the liver disease will be\n      assessed by Child-Turcotte Pugh score (CTP) and model for end stage liver disease (MELD)\n      score."
        }, 
        "brief_title": "To Compare the Efficacy of Combined Tenofovir Plus Telbivudine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Spontaneous Reactivation of Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Reactivation of CHB characterized by a rise in ALT level >5 times upper limit of\n             normal along with HBV DNA level >10^5 copies/ mL (> 1.8 X 10^4 IU/mL).\n\n        Exclusion Criteria:\n\n          1. Superinfection with other viruses (hepatitis E, A, D, or C)\n\n          2. other causes of chronic liver failure\n\n          3. coexistent hepatocellular carcinoma (HCC)\n\n          4. portal vein thrombosis\n\n          5. coexistent renal impairment\n\n          6. pregnancy\n\n          7. coinfection with human immunodeficiency virus (HIV)\n\n          8. patients who had received a previous course of any antiviral, immunomodulator or\n             cytotoxic/immunosuppressive therapy for chronic hepatitis or other illness within at\n             least the preceding 12 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732224", 
            "org_study_id": "ILBS-HBV Reactivation-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tenofovir", 
                "description": "Tenofovir (300 mg/day) plus telbivudine (600 mg/day).", 
                "intervention_name": "Tenofovir + Telbivudine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tenofovir + Telbivudine", 
                "description": "In tenofovir arm subjects will receive tenofovir (300 mg) once daily.", 
                "intervention_name": "Tenofovir", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tenofovir", 
                "Tenofovir disoproxil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 7, 2014", 
        "location": {
            "contact": {
                "email": "ankur.jindal3@gmail.com", 
                "last_name": "Dr Ankur Jindal, MD", 
                "phone": "+91-9582670984"
            }, 
            "contact_backup": {
                "email": "bhardwaj.ankit3@gmail.com", 
                "last_name": "Dr Ankit Bhardwaj", 
                "phone": "011-46300000", 
                "phone_ext": "1032"
            }, 
            "facility": {
                "address": {
                    "city": "New Delhi", 
                    "country": "India", 
                    "state": "Delhi", 
                    "zip": "110070"
                }, 
                "name": "Institute of Liver & Biliary Sciences (ILBS)"
            }, 
            "investigator": {
                "last_name": "Shiv Kumar Sarin", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective Randomized Controlled Study to Compare the Efficacy of Combined Tenofovir Plus Telbuvidine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B.", 
        "overall_contact": {
            "email": "ankur.jindal3@gmail.com", 
            "last_name": "Dr Ankur Jindal, MD", 
            "phone": "9582670984"
        }, 
        "overall_official": {
            "affiliation": "Institute of Liver & Biliary Sciences (ILBS).", 
            "last_name": "Shiv Kumar Sarin, DM", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Survival", 
            "safety_issue": "Yes", 
            "time_frame": "1 and 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732224"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Reduction in HBV DNA.", 
                "safety_issue": "No", 
                "time_frame": "7 days, 15 days, 1 month and 3 month"
            }, 
            {
                "measure": "Drug(s) related adverse effects/ side effects", 
                "safety_issue": "Yes", 
                "time_frame": "1 and 3 months"
            }, 
            {
                "measure": "Improvement in CTP and MELD scores", 
                "safety_issue": "No", 
                "time_frame": "1 and 3 months"
            }, 
            {
                "measure": "Alteration of  renal functions", 
                "safety_issue": "No", 
                "time_frame": "1 and 3 months"
            }
        ], 
        "source": "Institute of Liver and Biliary Sciences, India", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institute of Liver and Biliary Sciences, India", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}